Translation and Validation of the European Portuguese Version of the Quality of Life in Neurofibromatosis 1 Patients Scale (INF1-QoL)
DOI:
https://doi.org/10.46531/sinapse/AO/240009/2024Keywords:
Neurofibromatosis 1, Portugal, Psychometrics, Quality of Life, Reproducibility of Results, Surveys and Questionnaires, TranslationsAbstract
Introduction: The INF1-QoL questionnaire is an essential tool for assessing patients’ perceptions of their illness and its impact on their daily lives. This study aimed to obtain and validate the European Portuguese version of this questionnaire.Methods: The English version of INF1-QoL was translated using the “forward-backward” procedure. The questionnaire was administered to 78 adult patients with neurofibromatosis type 1.
Results: The Portuguese-translated version of INF1-QoL showed good internal consistency (Cronbach’s alpha: 0.86); the mean total INF1-QoL score was 9.11 (SD 6.35), the median was 8.00, with a range of 0–31, and no significant correlations with age, gender or education were found. The mean total EuroQol score was 6.6 (SD: 1.55), the median was 6. Total INF1-QoL score correlated with total EuroQol score (r=0.839, p<0.001. The highest impact on QoL were moderate or severe problems with anxiety and depression (28%) and the negative effects of NF1 on role and outlook on life (49%). The mean clinical severity score was 2.96 (SD: 0.987) correlating with the total INF1-QoL score (r=0.279, p=0.019) and correlated with the total EuroQol score (r=0.251, p=0.036). The clinical severity was mild in 34 (49%), moderate in 22 (31%), and severe in 14 (20%) of individuals.
Conclusion: Based on a detailed analysis of the results obtained, we found that the translated version of INF-QoL is a reliable and valid self-assessment screening tool for the Portuguese population with neurofibromatosis type 1.
Downloads
References
Ferner RE. Neurofibromatosis 1 and Neurofibromatosis 2: a twenty-first century perspective. Lancet Neurol. 2007;6:340–51.
Ferner RE. Psychological impact of the Neurofibromatoses. In: Ferner RE, Huson SM, Evans DG, editors. Neurofibromatoses in clinical practice. Berlin: Springer; 2011. p. 129-140.
Belzeaux R, Lançon C. Neurofibromatose de type 1. Troubles psychiatriques et altération de la qualité de vie. Presse Med. 2006;35:277-80.
Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013;114:257-62. doi: 10.1007/s11060-013-1195-2.
Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306:1437–40.
The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
Crawford HA, Barton B, Wilson MJ, Berman Y, McKelvey-Martin VJ, Morrison PJ et al. The impact of neurofibromatosis type 1 on the health and wellbeing of australian adults. J Genet Couns. 2015;24:931–44. doi: 10.1007/s10897-015-9829-5.
Bicudo NP, de Menezes Neto BF, da Silva de Avó LR, Germano CM, Melo DG. Quality of life in adults with neurofibromatosis 1 in Brazil. J Genet Couns. 2016;25:1063–74. doi: 10.1007/s10897-016-9939-8.
Granstrom S, Lanagenbruch A, Augsutin M, Mautner VF. Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology. 2012;224: 60–77. doi: 10.1159/000337548.
Ferner RE, Thomas M, Mercer G, Williams V, Leschziner GD, Afridi SK, et al. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire. Health Qual Life Outcomes. 2017;15:34. doi: 10.1186/s12955-017-0607-y.
Tsang S, Royse CF, Terkawi AS. Guidelines for developing, translating, and validating a questionnaire in perioperative and pain medicine. Saudi J Anaesth. 2017;11:S80-9. doi: 10.4103/sja.SJA_203_17.
Nutakki K, Hingtgen CM, Monahan P, Varni JW, Swigonski NL. Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity. Health Qual Life Outcomes. 2013;11:21. doi: 10.1186/1477-7525-11-21.
Brooks R. EuroQol: the current state of play. Health Policy.1996;37:53–72. doi: 10.1016/0168-8510(96)00822-6
EuroQoL. EQ-5D. 2023. [Accessed July 27, 2023] Available at: https://euroQoL.org/eq-5d-instruments
Ferreira PL, Ferreira LN, Pereira LN. Contributos para a Validação da Versão Portuguesa do EQ-5D. Acta Med Port. 2013;26:664-75.
Riccardi VM, Kleiner B. Neurofibromatosis: a neoplastic birth defect with two age peaks of severe problems. Birth Defects Orig Artic Ser. 1977;13:131-8.
Posit team. RStudio: Integrated Development Environment for R. [Accessed May 11, 2024] Available at: http://www.posit.co
Bicudo NP, de Menezes Neto BF, da Silva de Avó LR, Germano CM, Melo DG. Quality of Life in Adults with Neurofibromatosis 1 in Brazil. J Genet Couns. 2016;25:1063–74.
Brar KS, Trivedi C, Kaur N, Adnan M, Patel H, Beg U, et al. Prevalence of psychiatric comorbidities in patients with neurofibromatosis. Prim Care Companion CNS Disord. 2023;25:23m03514. doi: 10.4088/PCC.23m03514.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Leonor Brito-Santana, João Passos, Daniela Jeremias, Filipe Azevedo, Daniel Neto, Duarte Salgado
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
